{"transactions":[{"id":4613363,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:20:06.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":1,"expiration_date":"2035-06-10","underlying":"Ordinary Shares","underlying_shares":20174},"source":{"system":"sec-edgar","filing":"0001104659-26-106341","document":"tm2625057-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465926106341/tm2625057-6_4seq1.xml","form_type":"4"}},{"id":4613362,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:20:06.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19516,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":2.34,"expiration_date":"2034-05-10","underlying":"Ordinary Shares","underlying_shares":19516},"source":{"system":"sec-edgar","filing":"0001104659-26-106341","document":"tm2625057-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465926106341/tm2625057-6_4seq1.xml","form_type":"4"}},{"id":4613361,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:20:06.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19197,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":2.27,"expiration_date":"2033-05-11","underlying":"Ordinary Shares","underlying_shares":19197},"source":{"system":"sec-edgar","filing":"0001104659-26-106341","document":"tm2625057-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465926106341/tm2625057-6_4seq1.xml","form_type":"4"}},{"id":4613360,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:20:06.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":4.27,"expiration_date":"2032-06-15","underlying":"Ordinary Shares","underlying_shares":18604},"source":{"system":"sec-edgar","filing":"0001104659-26-106341","document":"tm2625057-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465926106341/tm2625057-6_4seq1.xml","form_type":"4"}},{"id":4613359,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-09T20:20:06.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34328,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to acquire Shares under the Issuer's equity plans that was outstanding as of immediately prior to the Effective Time ceased to represent a right to acquire Shares of the Issuer, and was converted into an option to acquire shares of Topco Common Stock and assumed by Topco on the same terms and conditions (including applicable vesting and exercisability conditions) as were applicable to such option immediately prior to the Effective Time."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."}],"balance_after":0,"derivative":{"exercise_price":17,"expiration_date":"2031-05-01","underlying":"Ordinary Shares","underlying_shares":34328},"source":{"system":"sec-edgar","filing":"0001104659-26-106341","document":"tm2625057-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465926106341/tm2625057-6_4seq1.xml","form_type":"4"}},{"id":4613358,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-09-09T20:20:06.000Z","date":"2026-09-09","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3000,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\" and together with the Ordinary Shares, the \"Shares\"), each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities transacted in connection with the Agreement and Plan of Merger, dated September 29, 2025, as amended (the \"Merger Agreement\") by and among the Issuer, Beacon Topco, Inc. (\"Topco\"), a Delaware corporation and a direct wholly owned subsidiary of the Issuer, Cdog Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Topco, and Clywedog Therapeutics, Inc., a Delaware corporation. On September 9, 2026 (the \"Effective Time\"), in connection with the effectiveness of the scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (the \"Scheme\") contemplated by the Merger Agreement, Topco acquired the entire issued share capital of the Issuer, resulting in the Issuer becoming a direct wholly owned subsidiary of Topco."},{"field":"shares","element":"transactionShares","label":"F3","text":"Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the \"Topco Common Stock\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement and in connection with the effectiveness of the Scheme, at the Effective Time, each Share of the Issuer was converted into the right to receive 0.111 shares of common stock, $0.0001 par value per share, of Topco (the \"Topco Common Stock\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-106341","document":"tm2625057-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1828185/000110465926106341/tm2625057-6_4seq1.xml","form_type":"4"}},{"id":723978,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2026-06-29T20:08:34.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":35.08,"value":210480.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on the earlier of June 26, 2027, and the date of the 2027 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting."}],"balance_after":16860,"derivative":{"exercise_price":35.08,"expiration_date":"2036-06-26","underlying":"Class A Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001627680-26-000006","document":"wk-form4_1782763711.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000162768026000006/wk-form4_1782763711.xml","form_type":"4"}},{"id":737767,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T20:19:52.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":39567,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 12, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":39567,"derivative":{"exercise_price":6.48,"expiration_date":"2036-06-11","underlying":"Series A Common Stock","underlying_shares":39567},"source":{"system":"sec-edgar","filing":"0001104659-26-074044","document":"tm2617570-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000110465926074044/tm2617570-1_4seq1.xml","form_type":"4"}},{"id":1113306,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2025-06-12T20:26:08.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":4000,"price":16.59,"value":66360.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests on the earlier of June 10, 2026, and the date of the 2026 annual general meeting of shareholders, subject to the director's continued service on the board of directors through such vesting."}],"balance_after":10860,"derivative":{"exercise_price":16.59,"expiration_date":"2035-06-10","underlying":"Class A Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001641489-25-000042","document":"wk-form4_1749759962.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000164148925000042/wk-form4_1749759962.xml","form_type":"4"}},{"id":1114878,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2025-06-11T21:15:31.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":20174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in full on the earlier of (i) June 10, 2026 or (ii) the next annual meeting of shareholders of the Issuer, subject to the Reporting Person's continued service as a director through the applicable vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":20174,"derivative":{"exercise_price":1,"expiration_date":"2035-06-10","underlying":"Ordinary Shares","underlying_shares":20174},"source":{"system":"sec-edgar","filing":"0001828185-25-000043","document":"wk-form4_1749676523.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000182818525000043/wk-form4_1749676523.xml","form_type":"4"}},{"id":1116285,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-10T21:41:17.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":27268,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over twelve (12) equal monthly installments following June 9, 2025, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":27268,"derivative":{"exercise_price":5.33,"expiration_date":"2035-06-08","underlying":"Series A Common Stock","underlying_shares":27268},"source":{"system":"sec-edgar","filing":"0001104659-25-058224","document":"tm2517621-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000110465925058224/tm2517621-5_4seq1.xml","form_type":"4"}},{"id":1440729,"issuer":{"id":5273,"kind":"organization","name":"Sagimet Biosciences Inc."},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-05T20:08:24.000Z","date":"2024-08-01","kind":"grant","planned":false,"acquired":true,"shares":113895,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable over thirty-six (36) equal monthly installments following August 1, 2024, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":113895,"derivative":{"exercise_price":3.48,"expiration_date":"2034-07-31","underlying":"Series A Common Stock","underlying_shares":113895},"source":{"system":"sec-edgar","filing":"0001104659-24-085818","document":"tm2420761-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000110465924085818/tm2420761-3_4seq1.xml","form_type":"4"}},{"id":1468110,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2024-06-27T20:37:18.000Z","date":"2024-06-25","kind":"grant","planned":false,"acquired":true,"shares":860,"price":17.22,"value":14809.2,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest in full on the one-year anniversary of the date of grant"}],"balance_after":6860,"derivative":{"exercise_price":17.22,"exercise_date":"2025-06-25","expiration_date":"2034-06-25","underlying":"Class A Common Stock","underlying_shares":860},"source":{"system":"sec-edgar","filing":"0001641489-24-000047","document":"wk-form4_1719520629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000164148924000047/wk-form4_1719520629.xml","form_type":"4"}},{"id":1468109,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2024-06-27T20:37:18.000Z","date":"2024-06-25","kind":"grant","planned":false,"acquired":true,"shares":2250,"price":17.22,"value":38745.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest monthly over the three year period following the date of grant."}],"balance_after":6000,"derivative":{"exercise_price":17.22,"expiration_date":"2034-06-25","underlying":"Class A Common Stock","underlying_shares":2250},"source":{"system":"sec-edgar","filing":"0001641489-24-000047","document":"wk-form4_1719520629.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000164148924000047/wk-form4_1719520629.xml","form_type":"4"}},{"id":1478916,"issuer":{"id":85383,"kind":"organization","name":"TREVENA INC","symbol":"TRVN"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T21:39:12.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":13700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the options shall vest in full on the first anniversary of the grant date, subject to the reporting person's continuous service through such vesting date."}],"balance_after":13700,"derivative":{"exercise_price":0.4,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":13700},"source":{"system":"sec-edgar","filing":"0001062993-24-012663","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000106299324012663/form4.xml","form_type":"4"}},{"id":1480665,"issuer":{"id":6614,"kind":"organization","name":"vTv Therapeutics Inc."},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2024-06-13T20:37:01.000Z","date":"2024-03-13","kind":"grant","planned":false,"acquired":true,"shares":3750,"price":16.04,"value":60150.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in monthly installments over the three-year period beginning March 13, 2024. The option was granted upon Dr. Phillips' appointment to the Board but was conditioned upon shareholder approval of the 2024 Equity Incentive Plan, which was approved by the shareholders on June 11, 2024."}],"balance_after":3750,"derivative":{"exercise_price":16.04,"expiration_date":"2034-03-13","underlying":"Class A Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001641489-24-000038","document":"wk-form4_1718311014.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000164148924000038/wk-form4_1718311014.xml","form_type":"4"}},{"id":1517448,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2024-05-14T20:19:12.000Z","date":"2024-05-10","kind":"grant","planned":false,"acquired":true,"shares":19516,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in full on the earlier of (i) May 10, 2025 or (ii) the next annual meeting of shareholders of the Issuer, subject to the Reporting Person's continued service as a director through the applicable vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":19516,"derivative":{"exercise_price":2.34,"expiration_date":"2034-05-10","underlying":"Ordinary Shares","underlying_shares":19516},"source":{"system":"sec-edgar","filing":"0001828185-24-000054","document":"wk-form4_1715717940.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000182818524000054/wk-form4_1715717940.xml","form_type":"4"}},{"id":1849509,"issuer":{"id":85383,"kind":"organization","name":"TREVENA INC","symbol":"TRVN"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-20T20:37:40.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":13700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the options shall vest in full on the first anniversary of the grant date, subject to the reporting person's continuous service through such vesting date."}],"balance_after":13700,"derivative":{"exercise_price":1.04,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":13700},"source":{"system":"sec-edgar","filing":"0001062993-23-013834","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000106299323013834/form4.xml","form_type":"4"}},{"id":1895011,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2023-05-12T20:07:00.000Z","date":"2023-05-11","kind":"grant","planned":false,"acquired":true,"shares":19197,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in full on the earlier of (i) May 11, 2024 or (ii) the next annual meeting of shareholders of the Issuer, subject to the Reporting Person's continued service as a director through the applicable vesting date."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":19197,"derivative":{"exercise_price":2.27,"expiration_date":"2033-05-11","underlying":"Ordinary Shares","underlying_shares":19197},"source":{"system":"sec-edgar","filing":"0001104659-23-059726","document":"tm2315647-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000110465923059726/tm2315647-4_4seq1.xml","form_type":"4"}},{"id":2022660,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2023-02-10T21:39:04.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":18604,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares underlying this option shall vest and become exercisable on June 15, 2023, with the remainder vesting in 24 equal monthly installments thereafter."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F2","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":18604,"derivative":{"exercise_price":4.27,"expiration_date":"2032-06-15","underlying":"Ordinary Shares","underlying_shares":18604},"source":{"system":"sec-edgar","filing":"0001104659-23-018607","document":"tm236344-4_5seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000110465923018607/tm236344-4_5seq1.xml","form_type":"5"}},{"id":2234157,"issuer":{"id":85383,"kind":"organization","name":"TREVENA INC","symbol":"TRVN"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-13T21:26:15.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date."}],"balance_after":100000,"derivative":{"exercise_price":0.43,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001062993-22-014807","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000106299322014807/form4.xml","form_type":"4"}},{"id":2686587,"issuer":{"id":85383,"kind":"organization","name":"TREVENA INC","symbol":"TRVN"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-02T21:00:45.000Z","date":"2021-05-28","kind":"grant","acquired":true,"shares":68577,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date."}],"balance_after":68577,"derivative":{"exercise_price":1.74,"expiration_date":"2031-05-28","underlying":"Common Stock","underlying_shares":68577},"source":{"system":"sec-edgar","filing":"0001429560-21-000004","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000142956021000004/edgar.xml","form_type":"4"}},{"id":2725108,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2021-05-06T20:25:50.000Z","date":"2021-05-04","kind":"purchase","acquired":true,"shares":3000,"price":17,"value":51000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001104659-21-062424","document":"tm2115262-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000110465921062424/tm2115262-2_4seq1.xml","form_type":"4"}},{"id":2730152,"issuer":{"id":9597,"kind":"organization","name":"Barinthus Biotherapeutics plc.","symbol":"BRNS"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2021-05-05T00:26:58.000Z","date":"2021-04-29","kind":"grant","acquired":true,"shares":34328,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in three equal annual installments, with the first installment vesting on April 29, 2022."},{"field":"derivative.underlying","element":"underlyingSecurityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."}],"balance_after":34328,"derivative":{"exercise_price":17,"expiration_date":"2031-04-29","underlying":"Ordinary Shares","underlying_shares":34328},"source":{"system":"sec-edgar","filing":"0001104659-21-061227","document":"tm2114558-23_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000110465921061227/tm2114558-23_4seq1.xml","form_type":"4"}},{"id":2978832,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-17T15:47:47.000Z","date":"2020-11-16","kind":"disposition_to_issuer","acquired":false,"shares":21289,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":21289},"source":{"system":"sec-edgar","filing":"0001104659-20-126331","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/792977/000110465920126331/a4.xml","form_type":"4"}},{"id":2978831,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-17T15:47:47.000Z","date":"2020-11-16","kind":"disposition_to_issuer","acquired":false,"shares":17326,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":17326},"source":{"system":"sec-edgar","filing":"0001104659-20-126331","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/792977/000110465920126331/a4.xml","form_type":"4"}},{"id":2978830,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-17T15:47:47.000Z","date":"2020-11-16","kind":"disposition_to_issuer","acquired":false,"shares":1200,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1200},"source":{"system":"sec-edgar","filing":"0001104659-20-126331","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/792977/000110465920126331/a4.xml","form_type":"4"}},{"id":2978829,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-17T15:47:47.000Z","date":"2020-11-16","kind":"disposition_to_issuer","acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an \"In-the-Money Cash Out Option\") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001104659-20-126331","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/792977/000110465920126331/a4.xml","form_type":"4"}},{"id":2978828,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-11-17T15:47:47.000Z","date":"2020-11-16","kind":"disposition_to_issuer","acquired":false,"shares":18949,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. (\"Parent\"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\") effective as of November 16, 2020 (the \"Effective Time\"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a \"Share\") was cancelled and converted into the right to receive $13.75 in cash (the \"Merger Consideration\") without interest and subject to applicable withholding taxes."},{"field":"shares","element":"transactionShares","label":"F2","text":"A portion of this amount consists of unvested restricted stock units (\"RSUs\"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. (\"Parent\"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the \"Merger\") effective as of November 16, 2020 (the \"Effective Time\"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a \"Share\") was cancelled and converted into the right to receive $13.75 in cash (the \"Merger Consideration\") without interest and subject to applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"A portion of this amount consists of unvested restricted stock units (\"RSUs\"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-20-126331","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/792977/000110465920126331/a4.xml","form_type":"4"}},{"id":3122743,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-04T16:50:39.000Z","date":"2020-06-02","kind":"grant","acquired":true,"shares":21289,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Grant of stock option pursuant to the Plan. This option will vest and become exercisable in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's 2020 annual meeting of stockholders."}],"balance_after":21289,"derivative":{"exercise_price":8.52,"expiration_date":"2030-06-02","underlying":"Common Stock","underlying_shares":21289},"source":{"system":"sec-edgar","filing":"0000792977-20-000062","document":"wf-form4_159130382017867.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/792977/000079297720000062/wf-form4_159130382017867.xml","form_type":"4"}},{"id":3122742,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-04T16:50:39.000Z","date":"2020-06-02","kind":"grant","acquired":true,"shares":10269,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the \"Issuer\"). These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's 2019 Equity Incentive Plan (the \"Plan\") that will vest in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's 2020 annual meeting of stockholders; however, delivery of the shares is deferred until the earlier of (a) one year from the date of grant and (b) the date of the director's separation from service to theIssuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."}],"balance_after":18949,"source":{"system":"sec-edgar","filing":"0000792977-20-000062","document":"wf-form4_159130382017867.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/792977/000079297720000062/wf-form4_159130382017867.xml","form_type":"4"}},{"id":3147272,"issuer":{"id":85383,"kind":"organization","name":"TREVENA INC","symbol":"TRVN"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-15T21:27:21.000Z","date":"2020-05-13","kind":"grant","acquired":true,"shares":64103,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date."}],"balance_after":64103,"derivative":{"exercise_price":1.05,"expiration_date":"2030-05-13","underlying":"Common Stock","underlying_shares":64103},"source":{"system":"sec-edgar","filing":"0001209191-20-029786","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000120919120029786/doc4.xml","form_type":"4"}},{"id":3519542,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-20T07:29:40.000Z","date":"2019-05-16","kind":"grant","acquired":true,"shares":17326,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Grant of stock option pursuant to the Plan. This option will vest and become exercisable in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's 2019 annual meeting of stockholders."}],"balance_after":17326,"derivative":{"exercise_price":10.78,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":17326},"source":{"system":"sec-edgar","filing":"0000792977-19-000105","document":"wf-form4_155835176487341.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/792977/000079297719000105/wf-form4_155835176487341.xml","form_type":"4"}},{"id":3519541,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-20T07:29:40.000Z","date":"2019-05-16","kind":"grant","acquired":true,"shares":8116,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the \"Issuer\"). These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's 2019 Equity Incentive Plan (the \"Plan\") that will vest in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's 2019 annual meeting of stockholders; however, delivery of the shares is deferred until the earlier of (a) one year from the date of grant and (b) the date of the director's separation from service to the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."}],"balance_after":8680,"source":{"system":"sec-edgar","filing":"0000792977-19-000105","document":"wf-form4_155835176487341.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/792977/000079297719000105/wf-form4_155835176487341.xml","form_type":"4"}},{"id":3523872,"issuer":{"id":85383,"kind":"organization","name":"TREVENA INC","symbol":"TRVN"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-16T21:34:17.000Z","date":"2019-05-16","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":1.34,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-19-030529","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000120919119030529/doc4.xml","form_type":"4"}},{"id":3557160,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-04-12T16:28:10.000Z","date":"2019-04-10","kind":"grant","acquired":true,"shares":1200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Grant of stock option pursuant to the Plan. This option will vest and become exercisable on May 1, 2019."}],"balance_after":1200,"derivative":{"exercise_price":12.92,"expiration_date":"2029-04-10","underlying":"Common Stock","underlying_shares":1200},"source":{"system":"sec-edgar","filing":"0000792977-19-000075","document":"wf-form4_155510087651744.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/792977/000079297719000075/wf-form4_155510087651744.xml","form_type":"4"}},{"id":3557159,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-04-12T16:28:10.000Z","date":"2019-04-10","kind":"grant","acquired":true,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Grant of stock option pursuant to the Plan. This option will vest and become exercisable in twenty-four equal monthly installments over two years from the date of grant."}],"balance_after":6000,"derivative":{"exercise_price":12.92,"expiration_date":"2029-04-10","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0000792977-19-000075","document":"wf-form4_155510087651744.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/792977/000079297719000075/wf-form4_155510087651744.xml","form_type":"4"}},{"id":3557158,"issuer":{"id":145305,"kind":"organization","name":"AMAG PHARMACEUTICALS, INC.","symbol":"AMAG"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-12T16:28:10.000Z","date":"2019-04-10","kind":"grant","acquired":true,"shares":564,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the \"Issuer\"). These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's Fourth Amended & Restated 2007 Equity Incentive Plan, as amended (the \"Plan\") that will vest on May 1, 2019; however, delivery of the shares is deferred until the earlier of (a) one year from the date of grant and (b) the date of the director's separation from service to the Issuer."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."}],"balance_after":564,"source":{"system":"sec-edgar","filing":"0000792977-19-000075","document":"wf-form4_155510087651744.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/792977/000079297719000075/wf-form4_155510087651744.xml","form_type":"4"}},{"id":3928244,"issuer":{"id":85383,"kind":"organization","name":"TREVENA INC","symbol":"TRVN"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-17T21:10:59.000Z","date":"2018-05-16","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":1.84,"expiration_date":"2028-05-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-18-031038","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000120919118031038/doc4.xml","form_type":"4"}},{"id":4291115,"issuer":{"id":85383,"kind":"organization","name":"TREVENA INC","symbol":"TRVN"},"owners":[{"id":34812,"kind":"person","name":"Phillips Anne M.","position":1,"cik":"0001627680","reported_name":"Phillips Anne M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-06T20:45:31.000Z","date":"2017-05-17","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":3.08,"expiration_date":"2027-05-17","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-17-038144","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1627680/000120919117038144/doc4.xml","form_type":"4"}}]}